AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8874330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 145
Study 8874330 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 145
Study 1781796 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (1‐amino‐3,5‐dimethyl‐adamantane hydrochloride)
Number of subjects: 66
Study 1781796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 548558 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha gel
Number of subjects: 100
Study 548558 — intervention group
Group type: COMPARATOR
Intervention: PGE2 tablets
Number of subjects: 100
Study 548558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31023383 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information sheets provided to proxies
Number of subjects: 30
Study 28265144 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston Technique
Number of subjects: 24
Study 28265144 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching
Number of subjects: 24
Study 25757503 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 20
Study 23670880 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation of arrhythmogenic pulmonary veins (aPV) in AG group (n=105)
Number of subjects: 207
Study 23670880 — intervention group
Group type: COMPARATOR
Intervention: Isolation of all pulmonary veins (VG group, n=102)
Number of subjects: 207
Study 21383110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 56
Study 21383110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21383110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MPH dose
Number of subjects: 56
Study 21383110 — intervention group
Group type: EXPERIMENTAL
Intervention: High MPH dose
Number of subjects: 56
Study 19823178 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks
Number of subjects: 53
Study 19823178 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks in group I (ED)
Number of subjects: 53
Study 19823178 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks in group II (no ED)
Number of subjects: 53
Study 17076775 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 30
Study 17076775 — intervention group
Group type: COMPARATOR
Intervention: Flap Surgery
Number of subjects: 30
Study 15505185 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency left dorsolateral prefrontal rTMS
Number of subjects: 20
Study 15505185 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study 11504824 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, 200 mg daily
Number of subjects: 6
Study 11504824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9011704 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm bypass (37 degrees C, hematocrit 23%, pump flow 150 ml/kg per minute)
Number of subjects: 40
Study 9011704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic bypass (22 degrees C)
Number of subjects: 40
Study 9011704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic low-flow bypass (75 ml/kg per minute)
Number of subjects: 40
Study 9011704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic low-hematocrit bypass (hematocrit 16%)
Number of subjects: 40
Study 8215281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg orally)
Number of subjects: 181
Study 8215281 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg intramuscularly)
Number of subjects: 181
Study 2894217 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551 (150 mg daily for 7 days)
Number of subjects: 0
Study 2894217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily for 7 days)
Number of subjects: 0
Study 2894217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29680317 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 29680317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27237130 — intervention group
Group type: EXPERIMENTAL
Intervention: DNACPR
Number of subjects: 231
Study 27237130 — intervention group
Group type: EXPERIMENTAL
Intervention: UFTO
Number of subjects: 231
Study 27237130 — intervention group
Group type: COMPARATOR
Intervention: No-form
Number of subjects: 231
Study 25167224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to information about overdiagnosis in breast cancer screening
Number of subjects: 2272
Study 25167224 — intervention group
Group type: EXPERIMENTAL
Intervention: Information format providing an estimate of the rate of overdiagnosis (simple ratio format)
Number of subjects: 2272
Study 25167224 — intervention group
Group type: EXPERIMENTAL
Intervention: General information on overdiagnosis
Number of subjects: 2272
Study 24332065 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proteomics analysis
Number of subjects: 3
Study 24332065 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen I expression
Number of subjects: 3
Study 24332065 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of collagen I degradation telopeptide (CTx)
Number of subjects: 3
Study 20584877 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg x 1 x IV + 90 mg x 1 x day V-VII
Number of subjects: 100
Study 20584877 — intervention group
Group type: COMPARATOR
Intervention: Tramadol sustained-release 100 mg x 2 x VII
Number of subjects: 100
Study 18835335 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine irradiation from a 3G mobile phone
Number of subjects: 29
Study 18835335 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 29
Study 16401321 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 249
Study 12878617 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 40
Study 12878617 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 40
Study 10394873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of ferric ammonium citrate
Number of subjects: 99
Study 10394873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg of ferric ammonium citrate
Number of subjects: 99
Study 10394873 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study 9116394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate (300 mg/day for 4 weeks every 4 months)
Number of subjects: 121
Study 9116394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate (150 mg/day for 4 weeks every 2 months)
Number of subjects: 121
Study 9116394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 1519713 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 41
Study 1519713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6657002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (200 mg orally)
Number of subjects: 36
Study 31688645 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20
Study 31481366 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London model of care
Number of subjects: 2138
Study 31481366 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2138
Study 28125735 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback training (4 weekly sessions, 60-min each)
Number of subjects: 13
Study 28125735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neurofeedback)
Number of subjects: 13
Study 25838513 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 100
Study 25838513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23429593 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg aflibercept, 1-hour intravenous
Number of subjects: 87
Study 23429593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21055873 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy (RF group; n=19)
Number of subjects: 38
Study 21055873 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 38
Study 19707148 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 70
Study 19707148 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 70
Study 16552196 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 34
Study 16552196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch (AP) construction
Number of subjects: 34
Study 16552196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch with preserved duodenal passage (APwPDP) reconstruction
Number of subjects: 34
Study 16552196 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 14505296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/d)
Number of subjects: 395
Study 14505296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 14505296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (147 mg)
Number of subjects: 395
Study 14505296 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 395
Study 10381787 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day meloxicam
Number of subjects: 11
Study 10381787 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day meloxicam
Number of subjects: 11
Study 10381787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9025799 — intervention group
Group type: EXPERIMENTAL
Intervention: M40 mask
Number of subjects: 9
Study 10149615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stems at 12 weeks
Number of subjects: 60
Study 10149615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stems at 6 weeks
Number of subjects: 60
Study 10149615 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stems at 12 weeks
Number of subjects: 60
Study 10149615 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stems at 6 weeks
Number of subjects: 60
Study 10149615 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (hydroxyapatite and uncoated)
Number of subjects: 60
Study 6296755 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell pertussis antigen with aluminum phosphate adjuvant (WcPh)
Number of subjects: 0
Study 6296755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled whole cell groups
Number of subjects: 0
Study 6296755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled whole cell antigen group
Number of subjects: 0
Study 6296755 — intervention group
Group type: COMPARATOR
Intervention: Individual vaccines
Number of subjects: 0
Study 30913161 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent Stroop task (high cognitive load)
Number of subjects: 13
Study 30913161 — intervention group
Group type: COMPARATOR
Intervention: Congruent Stroop task (low cognitive load)
Number of subjects: 13
Study 28375032 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of dalteparin sodium (DS)
Number of subjects: 24
Study 28375032 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of dalteparin sodium (DS)
Number of subjects: 24
Study 27323934 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise and structured advice
Number of subjects: 33
Study 27323934 — intervention group
Group type: COMPARATOR
Intervention: Structured advice only
Number of subjects: 33
Study 24246908 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy screening
Number of subjects: 203
Study 24246908 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 203
Study 22184366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed notification of the fracture sent to primary care physicians (n = 1363)
Number of subjects: 4264
Study 22184366 — intervention group
Group type: EXPERIMENTAL
Intervention: Notifications sent to both physicians and patients (n = 1421)
Number of subjects: 4264
Study 22184366 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 1480)
Number of subjects: 4264
Study 22184366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups 2 and 3
Number of subjects: 4264
Study 22184366 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (physician notification)
Number of subjects: 4264
Study 22184366 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (physician and patient notification)
Number of subjects: 4264
Study 19159026 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized device (Wand, Milestone Scientific)
Number of subjects: 104
Study 19159026 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 104
Study 17034977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography method for SMX and TMP determination
Number of subjects: 0
Study 16277783 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (4.2 g/d)
Number of subjects: 53
Study 16277783 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 53
Study 11897986 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg intranasally once daily)
Number of subjects: 143
Study 11897986 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10 mg orally once daily)
Number of subjects: 143
Study 11897986 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (14-day courses as needed)
Number of subjects: 143
Study 10212740 — intervention group
Group type: EXPERIMENTAL
Intervention: Deluded participants
Number of subjects: 60
Study 10212740 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 60
Study 10212740 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 60
Study 7573647 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises using elastic tubing (Sport Cord)
Number of subjects: 100
Study 7573647 — intervention group
Group type: COMPARATOR
Intervention: Open kinetic chain exercises using conventional physical therapy equipment
Number of subjects: 100
Study 2110972 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma (0.03 mg/m2, 0.3 mg/m2, 1 mg/m2, 3 mg/m2)
Number of subjects: 21
Study 2110972 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 21
Study 506644 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 grams of lecithin administered orally
Number of subjects: 25
Study 506644 — intervention group
Group type: COMPARATOR
Intervention: 2 grams of placebo administered orally
Number of subjects: 25
Study 30653242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg/day for 4 weeks
Number of subjects: 58
Study 30653242 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 58
Study 27671621 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index (IPI) group
Number of subjects: 170
Study 27671621 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded recording of capnography)
Number of subjects: 170
Study 27671621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 27671621 — intervention group
Group type: EXPERIMENTAL
Intervention: IPI group
Number of subjects: 170
Study 27671621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study 26349127 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik Water Flosser (WF) plus a manual toothbrush
Number of subjects: 69
Study 26349127 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Air Floss Pro (AFP) plus a manual toothbrush
Number of subjects: 69
Study 23132349 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo cryoballoon ablation
Number of subjects: 47
Study 21514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeldicks light intervention (physical activity training, nutrition education, behavior counseling)
Number of subjects: 76
Study 21514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeldicks light intervention
Number of subjects: 76
Study 19658274 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for 10-14 days
Number of subjects: 22
Study 19658274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium sulfate infusion)
Number of subjects: 22
Study 16675938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg initial dose, 0.03 mg/kg maintenance)
Number of subjects: 177
Study 16675938 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg/kg initial dose, 0.02 mg/kg maintenance)
Number of subjects: 177
Study 16675938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 177
Study 16675938 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 177
Study 12145008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soyfood diet (50 g soy protein and 73 mg isoflavones daily)
Number of subjects: 41
Study 12145008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soyfood diet (52 g soy protein and 10 mg isoflavones daily)
Number of subjects: 41
Study 12145008 — intervention group
Group type: COMPARATOR
Intervention: Both soy diets (high and low isoflavone)
Number of subjects: 41
Study 12145008 — intervention group
Group type: COMPARATOR
Intervention: Soy diets (high and low isoflavone)
Number of subjects: 41
Study 10099907 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (70 mmol infused over 24 h)
Number of subjects: 59
Study 10099907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8651412 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure during pregnancy
Number of subjects: 317
Study 8651412 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased basal metabolic rate
Number of subjects: 317
Study 2110336 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine/2-PAM chloride
Number of subjects: 0
Study 2110336 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 2110336 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-humidity (95 degrees F/60% RH)
Number of subjects: 0
Study 2110336 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-humidity (70 degrees F/30% RH)
Number of subjects: 0
Study 382381 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 29284183 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral food challenge (OFC)
Number of subjects: 96
Study 26867046 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care consisting of chemotherapy followed by endocrine therapy.
Number of subjects: 350
Study 26867046 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX test used to assign patients to treatment.
Number of subjects: 350
Study 26867046 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care if 'recurrence score' (RS) was > 25 or endocrine therapy alone if RS was ≤ 25.
Number of subjects: 350
Study 26867046 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter analysis performed on 302 tumour samples.
Number of subjects: 350
Study 26867046 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economics modelling for multiparameter testing.
Number of subjects: 350
Study 25616289 — intervention group
Group type: EXPERIMENTAL
Intervention: Huai Qi Huang granules plus glucocorticoid
Number of subjects: 42
Study 25616289 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid alone
Number of subjects: 42
Study 23731228 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention (home visits by trained volunteers)
Number of subjects: 15615
Study 23731228 — intervention group
Group type: COMPARATOR
Intervention: Control zones
Number of subjects: 15615
Study 20054285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 0
Study 20054285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbismuth quadruple therapy
Number of subjects: 0
Study 20054285 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 0
Study 18239640 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 306
Study 18239640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 18239640 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat and Placebo
Number of subjects: 306
Study 16382603 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D displays with appropriate cues (e.g., shadows)
Number of subjects: 0
Study 16382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation icon and ExoVis displays
Number of subjects: 0
Study 16382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined displays (2D/3D)
Number of subjects: 0
Study 16382603 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip plane displays
Number of subjects: 0
Study 12752488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 177
Study 12752488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 10218722 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg/day (n = 37)
Number of subjects: 152
Study 10218722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 100 mg/day (n = 38)
Number of subjects: 152
Study 10218722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol, 10 mg/day (n = 39)
Number of subjects: 152
Study 10218722 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol, 400 mg/day (n = 38)
Number of subjects: 152
Study 10165968 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone mammography counseling
Number of subjects: 90
Study 10165968 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling and a letter
Number of subjects: 90